Hyloris Pharmaceuticals SA banner

Hyloris Pharmaceuticals SA
LSE:0AB6

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
LSE:0AB6
Watchlist
Price: 6.26 EUR -7.12% Market Closed
Market Cap: €1.7m

Hyloris Pharmaceuticals SA
Investor Relations

Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Stijn Van Rompay
Co-Founder, Co-CEO & Director
No Bio Available
Mr. Thomas Jacobsen
Co-Founder, Co-CEO, Chief Business Development Officer & Executive Director
No Bio Available
Mr. Jean-Luc Vandebroek
Chief Financial Officer
No Bio Available
Dr. Dietmar Aichhorn Ph.D.
Chief Operating Officer
No Bio Available
Mr. Sven Watthy
Investor Relations Manager & Communications manager
No Bio Available
Mr. Koenraad Van Der Elst
Chief Legal Officer
No Bio Available

Contacts

Address
LIEGE
Liege
Boulevard Gustave Kleyer 17
Contacts
+3243460207
hyloris.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett